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Appropriately staging lung cancer is critical for at least four reasons.1 First, the stagingsystem provides a standardized description of the disease, a common language, if you
will, for different physicians in different health care settings to understand the extent of
a given patient’s disease. Second, and perhaps the most important rationale for staging, is
that stage dictates treatment and the treatment regimens vary considerably by stage. For
example, currently stage 1A lung cancer is treated with surgery alone, stage 2 and resected
stage 3A lung cancers are treated surgically followed by adjuvant chemotherapy, bulky
stage 3A lung cancer is treated with combination chemoradiotherapy, and metastatic lung
cancer is treated with chemotherapy alone. Third, in a crude way, stage predicts survival.
Fourth, the staging system allows us to facilitate research and compare results of different
clinical trials. Historically, much credit should be given to the pioneers who described and
revised the current staging system in lung cancer.2–5 It is through their efforts that we were
able to provide a framework for treating those with lung cancer and a base on which to
build cancer clinical trials. In 1974, the first TNM staging classification for non-small cell
lung cancer was undertaken by the American Joint Committee for Cancer Staging
(AJCC).2,3 It was based on analysis of 2155 patients with lung cancer. In 1986, members
of the AJCC, the Union Internationale Contre le Cancer (UICC), as well as Japanese and
German representatives proposed a revised international staging system for lung cancer
based on analysis of 3753 lung cancer patients who had care provided at the M.D.
Anderson Cancer Center and the North American Lung Cancer study group’s reference
center for anatomic and pathologic classification of lung cancer.4 The most recent
revision, published in 1997, was based on 5319 patients treated for lung cancer between
1975 and 1988 at the aforementioned sites.5 Several important changes were made to the
most recent staging system. Stages I and II were divided into IA and IB and IIA and IIB,
respectively. T3N0M0 was down-staged to stage IIB. Tumors with satellite nodules in the
same lobe were designated as T4 (and thus stage 3B), and those with a primary tumor and
satellite nodules in other lobes were designated M1. The current staging system has been
in place for 10 years, having undergone two major revisions since its introduction in 1974.
Although this classification system has served us well, there are clearly limitations.1
Many of the data on which the staging system is based are single-institution data, from a
dedicated cancer center, with expertise in accurately staging patients with lung cancer.
Unfortunately, the data set represents a small geographic area in North America and one
wonders whether the results are generalizable to other parts of the world. Further, many
of the cases were surgical cases. Although 5000 or so cases of lung cancer may seem like
enough, there were instances in which certain clinical presentations (e.g., primary tumors
with satellite nodules) had very few cases available for analysis. Last, although the data
were internally validated, extensive external validation using other data sets was not
performed.
This leads us to the to the massive undertaking of the International Association for
the Study of Lung Cancer and the article by Goldstraw et al.6 in this issue of the Journal
of Thoracic Oncology. They propose for consideration a revision of the TNM stage
groupings that addresses some of the methodologic pitfalls of the current system and a few
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of the clinical scenarios that needed clarification and perhaps
new classification.7–9 The methodology deserves a closer
look. An international staging committee was formed with
worldwide expert multidisciplinary representation in thoracic
oncology forming the nucleus. Equally critical to the success
of this project was that they were supported by the Cancer
Research and Biostatistics group with extensive expertise in
managing and analyzing cancer data sets. There are more
than 100,000 entries in the data set representing 23 institu-
tions in 12 countries in Europe, North America, and Aus-
tralasia. To say that the data are robust would be an under-
statement. In my view, the most important component of their
work was the painstaking validation of their findings. That is
to say that when changes in the staging system were proposed
based on survival, they were both internally validated using a
subset of the larger data set and externally validated using the
Surveillance Epidemiology and End Results cancer registry.
Are the data perfect? Not really. Many of the data entered
were not collected with the expressed purpose of staging lung
cancer, and some of the data are incomplete. In the future, a
prospective database will overcome this obstacle. Is this the
best data set available? Absolutely, and it is generalizable to
patients with lung cancer all over the world.
Some of the changes that they propose make eminent
clinical sense. The main suggestions are in the T and M
classification with N status remaining the same. They found
that tumor size was an important prognosticator and recom-
mend that the T factor be subdivided based on five different-
size criteria. Because survivorship was better, they recom-
mend reclassification of primary tumors with satellite nodules
in the same lobe from T4 to T3 and that additional nodules in
a different lobe of the ipsilateral lung moved from an M1
designation to T4. Malignant pleural effusion is currently
classified as T4 or so-called wet 3B disease, despite the
fact that the survival of patients in this group is much more
like that of metastatic rather than locally advanced disease.
They appropriately propose moving these patients to M1.
One final change is that they recommend the M status be
split into M1a (metastatic disease confined to the chest)
and M1b (extrathoracic metastatic disease) based on the
finding that survival is better in those with metastatic
disease confined to the thorax.
If these recommendations are adopted, how long are
they likely to last? That is hard to say. Even with the size and
scope of this undertaking, the staging system remains a
relatively crude predictor of survival. Recent forays into
tumor protein expression and cancer genomics have pro-
vided a glimpse into how we may improve our ability to
predict outcome among those within a given stage group-
ing.10 –12 One can envision a time in the not too distant
future when stage will be based on both the TNM classi-
fication and molecular diagnostics. Until then, let us ad-
mire the work of those who built the staging system over
the past 30 years and embrace the proposal for a new
classification for lung cancer.
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